O	0	9	Incidence
O	10	12	of
O	13	21	invasive
O	22	28	breast
O	29	35	cancer
O	36	38	in
O	39	53	postmenopausal
O	54	59	women
O	60	65	after
O	66	81	discontinuation
O	82	84	of
O	85	89	long
O	89	90	-
O	90	94	term
B-intervention	95	105	raloxifene
O	106	120	administration
O	120	121	.

B-eligibility	122	136	Postmenopausal
I-eligibility	137	142	women
I-eligibility	143	147	with
I-eligibility	148	160	osteoporosis
O	161	164	had
O	165	166	a
O	167	169	66
O	169	170	%
O	171	179	relative
O	180	184	risk
O	185	194	reduction
O	195	198	for
O	199	207	invasive
O	208	214	breast
O	215	221	cancer
O	222	226	over
O	227	228	8
O	229	234	years
O	235	237	of
O	238	248	raloxifene
O	249	256	therapy
O	257	259	in
O	260	263	the
O	264	274	randomized
O	274	275	,
O	276	283	placebo
O	283	284	-
O	284	294	controlled
O	295	296	4
O	296	297	-
O	297	301	year
O	302	306	MORE
O	307	308	(
O	308	316	Multiple
O	317	325	Outcomes
O	326	328	of
O	329	339	Raloxifene
O	340	350	Evaluation
O	350	351	)
O	352	357	trial
O	358	361	and
O	362	365	the
O	366	370	CORE
O	371	372	(
O	372	382	Continuing
O	383	391	Outcomes
O	392	400	Relevant
O	401	403	to
O	404	410	Evista
O	410	411	)
O	412	417	trial
O	417	418	,
O	419	420	a
O	421	422	4
O	422	423	-
O	423	427	year
O	428	434	follow
O	434	435	-
O	435	437	up
O	438	440	to
O	441	445	MORE
O	445	446	.

O	447	450	The
O	451	456	first
O	457	461	post
O	462	465	hoc
O	466	474	analysis
O	475	483	examined
O	484	487	the
O	488	495	effects
O	496	498	of
O	499	509	raloxifene
O	510	512	on
O	513	516	the
O	517	527	cumulative
O	528	537	incidence
O	538	540	of
O	541	549	invasive
O	550	556	breast
O	557	563	cancer
O	564	566	on
O	567	568	a
O	569	575	yearly
O	576	581	basis
O	581	582	.

O	583	590	Another
O	591	599	analysis
O	600	608	compared
O	609	612	the
O	613	622	incidence
O	623	625	of
O	626	634	invasive
O	635	641	breast
O	642	648	cancer
O	649	651	in
B-total-participants	652	656	3967
O	657	665	patients
O	666	669	who
O	670	679	continued
O	680	690	raloxifene
O	691	694	for
O	695	696	8
O	697	702	years
O	703	704	(
O	704	707	RLX
O	707	708	-
O	708	709	C
O	709	710	,
O	711	712	n
O	713	714	=
B-intervention-participants	715	719	2280
O	719	720	)
O	720	721	,
O	722	734	discontinued
O	735	745	raloxifene
O	746	751	after
O	752	753	4
O	754	759	years
O	760	762	in
O	763	767	MORE
O	768	769	(
O	769	772	RLX
O	772	773	-
O	773	774	D
O	774	775	,
O	776	777	n
O	778	779	=
B-intervention-participants	780	783	401
O	783	784	)
O	784	785	,
O	786	788	or
O	789	793	took
B-control	794	801	placebo
O	802	803	(
O	803	804	n
O	805	806	=
B-control-participants	807	811	1286
O	811	812	)
O	813	816	for
O	817	818	a
O	819	823	mean
O	824	825	2
O	825	826	.
O	826	827	9
O	828	833	years
O	833	834	'
O	835	844	treatment
O	845	853	duration
O	854	855	(
O	855	857	57
O	857	858	,
O	858	861	338
O	862	869	patient
O	869	870	-
O	870	875	years
O	875	876	)
O	876	877	.

O	878	881	The
O	882	892	unadjusted
B-outcome	893	899	breast
I-outcome	900	906	cancer
I-outcome	907	916	incidence
I-outcome	917	921	rate
O	922	925	was
B-cv-bin-abs	926	927	5
I-cv-bin-abs	927	928	.
I-cv-bin-abs	928	930	39
O	931	934	per
B-control-participants	935	939	1000
O	940	947	patient
O	947	948	-
O	948	953	years
O	954	956	in
O	957	960	the
O	961	968	placebo
O	969	974	group
O	975	983	compared
O	984	988	with
B-iv-bin-abs	989	990	2
I-iv-bin-abs	990	991	.
I-iv-bin-abs	991	993	26
O	994	996	in
O	997	1000	the
O	1001	1004	RLX
O	1004	1005	-
O	1005	1006	C
O	1007	1012	group
O	1013	1014	(
O	1014	1020	hazard
O	1021	1026	ratio
O	1027	1028	[
O	1028	1030	HR
O	1030	1031	]
O	1031	1032	,
O	1033	1034	0
O	1034	1035	.
O	1035	1037	41
O	1038	1039	[
O	1039	1041	95
O	1041	1042	%
O	1043	1045	CI
O	1046	1047	0
O	1047	1048	.
O	1048	1050	21
O	1050	1051	-
O	1051	1052	0
O	1052	1053	.
O	1053	1055	81
O	1055	1056	]
O	1056	1057	)
O	1058	1061	and
B-iv-bin-abs	1062	1063	3
I-iv-bin-abs	1063	1064	.
I-iv-bin-abs	1064	1066	59
O	1067	1069	in
O	1070	1073	the
O	1074	1077	RLX
O	1077	1078	-
O	1078	1079	D
O	1080	1085	group
O	1086	1087	(
O	1087	1089	HR
O	1089	1090	,
O	1091	1092	0
O	1092	1093	.
O	1093	1095	69
O	1096	1097	[
O	1097	1099	95
O	1099	1100	%
O	1101	1103	CI
O	1104	1105	0
O	1105	1106	.
O	1106	1108	23
O	1108	1109	-
O	1109	1110	2
O	1110	1111	.
O	1111	1113	01
O	1113	1114	]
O	1114	1115	)
O	1115	1116	.

O	1117	1124	Because
O	1125	1128	the
O	1129	1135	choice
O	1136	1138	of
O	1139	1145	taking
O	1146	1149	the
O	1150	1155	study
O	1156	1160	drug
O	1161	1164	was
O	1165	1168	not
O	1169	1179	randomized
O	1180	1182	in
O	1183	1187	CORE
O	1187	1188	,
O	1189	1199	propensity
O	1200	1206	scores
O	1207	1211	were
O	1212	1216	used
O	1217	1219	to
O	1220	1226	adjust
O	1227	1230	for
O	1231	1240	potential
O	1241	1251	imbalances
O	1252	1254	in
O	1255	1263	baseline
O	1264	1279	characteristics
O	1280	1286	before
O	1287	1291	CORE
O	1291	1292	.

O	1293	1300	Results
O	1301	1306	after
O	1307	1317	adjustment
O	1318	1320	by
O	1321	1324	the
O	1325	1335	propensity
O	1336	1341	score
O	1342	1348	method
O	1349	1353	were
O	1354	1361	similar
O	1362	1364	to
O	1365	1368	the
O	1369	1379	unadjusted
O	1380	1387	results
O	1387	1388	.

O	1389	1393	This
O	1394	1402	analysis
O	1403	1411	suggests
O	1412	1413	a
O	1414	1424	persistent
O	1425	1431	effect
O	1432	1435	for
O	1436	1442	breast
O	1443	1449	cancer
O	1450	1454	risk
O	1455	1464	reduction
O	1465	1467	in
O	1468	1476	patients
O	1477	1480	who
O	1481	1493	discontinued
O	1494	1504	raloxifene
O	1504	1505	,
O	1506	1514	although
O	1515	1519	this
O	1520	1530	conclusion
O	1531	1533	is
O	1534	1541	limited
O	1542	1544	by
O	1545	1548	the
O	1549	1554	small
O	1555	1561	sample
O	1562	1566	size
O	1566	1567	.
